Bayesian Multi‐Criteria Decision Analysis of Net Clinical Benefit in <scp>ARASENS</scp> : Overall and Japanese Subgroup Results
Bayesian MCDA integrated multiple clinical endpoints to examine how differing value preferences influence decision-making. Scenario-based analysis demonstrated a consistent benefit of adding darolutamide to ADT and docetaxel, while revealing that varying efficacy-safety weightings affected confidence in overall utility among Japanese.
Authors
- Soichiro Yoshida
- Hideto Fukushima
- Kenji Tanabe
- Yosuke Yasuda
- Hitoshi Masuda
- Hiroyuki Sato
- Shugo Yajima
- Yasuhisa Fujii
- Wei Chen
- Hajime Tanaka
- Akihiro Hirakawa (ORCID: https://orcid.org/0000-0002-1193-8104)
Institutions
- Fourth People's Hospital of Sichuan Province (CN)
- National Cancer Center Hospital East (JP)
- Zigong First People's Hospital (CN)
- Institute of Science Tokyo (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1111/iju.70384
- Primary Topic
- Advanced Causal Inference Techniques
- Type
- article
- Field-Weighted Citation Impact
- 0.00